Rida's very likely superior performances in the largest(softtissue)subpopulations(reviewed here ad nauseum in the past) have to bolster the case for overall approval.
In addition, once that happens, it's likely to supercharge the development and acceptance of Rida in other indications.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.